MEI Pharma (MEIP) Competitors $2.05 +0.01 (+0.49%) Closing price 05/1/2025 03:59 PM EasternExtended Trading$2.01 -0.04 (-2.15%) As of 05/1/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MEIP vs. OKYO, PEPG, IMRX, KPTI, PMVP, AVTX, CTOR, PRLD, QNCX, and ICCCShould you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include OKYO Pharma (OKYO), PepGen (PEPG), Immuneering (IMRX), Karyopharm Therapeutics (KPTI), PMV Pharmaceuticals (PMVP), Avalo Therapeutics (AVTX), Citius Oncology (CTOR), Prelude Therapeutics (PRLD), Quince Therapeutics (QNCX), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. MEI Pharma vs. OKYO Pharma PepGen Immuneering Karyopharm Therapeutics PMV Pharmaceuticals Avalo Therapeutics Citius Oncology Prelude Therapeutics Quince Therapeutics ImmuCell MEI Pharma (NASDAQ:MEIP) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings. Which has more risk and volatility, MEIP or OKYO? MEI Pharma has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.32, meaning that its share price is 132% less volatile than the S&P 500. Does the media prefer MEIP or OKYO? In the previous week, OKYO Pharma had 3 more articles in the media than MEI Pharma. MarketBeat recorded 6 mentions for OKYO Pharma and 3 mentions for MEI Pharma. OKYO Pharma's average media sentiment score of 0.60 beat MEI Pharma's score of 0.29 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MEI Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OKYO Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, MEIP or OKYO? MEI Pharma has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMEI Pharma$65.30M0.21$17.78M-$5.73-0.36OKYO PharmaN/AN/A-$16.83MN/AN/A Is MEIP or OKYO more profitable? OKYO Pharma's return on equity of 0.00% beat MEI Pharma's return on equity.Company Net Margins Return on Equity Return on Assets MEI PharmaN/A -84.92% -67.53% OKYO Pharma N/A N/A N/A Do institutionals & insiders have more ownership in MEIP or OKYO? 52.4% of MEI Pharma shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 3.1% of MEI Pharma shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer MEIP or OKYO? OKYO Pharma has a consensus target price of $7.00, suggesting a potential upside of 347.28%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts clearly believe OKYO Pharma is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MEI Pharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in MEIP or OKYO? MEI Pharma received 411 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 63.21% of users gave MEI Pharma an outperform vote. CompanyUnderperformOutperformMEI PharmaOutperform Votes42163.21% Underperform Votes24536.79% OKYO PharmaOutperform Votes10100.00% Underperform VotesNo Votes SummaryOKYO Pharma beats MEI Pharma on 9 of the 14 factors compared between the two stocks. Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MEIP vs. The Competition Export to ExcelMetricMEI PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.66M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.367.3222.5118.54Price / Sales0.21241.49397.62103.30Price / Cash0.4465.8538.1834.62Price / Book0.626.486.734.25Net Income$17.78M$143.41M$3.22B$248.18M7 Day Performance-2.38%2.58%1.38%1.03%1 Month Performance-4.65%5.00%2.79%2.70%1 Year Performance-33.01%-3.72%15.41%4.05% MEI Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MEIPMEI Pharma1.6041 of 5 stars$2.05+0.5%N/A-33.0%$13.66M$65.30M-0.36100Upcoming EarningsShort Interest ↑Gap UpOKYOOKYO Pharma2.7719 of 5 stars$1.55+2.6%$7.00+351.6%+4.3%$52.45MN/A0.007Short Interest ↓News CoveragePositive NewsPEPGPepGen2.7875 of 5 stars$1.60+4.6%$10.33+545.8%-89.4%$52.31MN/A-0.5430Positive NewsIMRXImmuneering3.7773 of 5 stars$1.45flat$12.50+762.1%-15.7%$52.18M$320,000.00-0.7460Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap UpKPTIKaryopharm Therapeutics3.6351 of 5 stars$6.07+8.0%$57.50+847.3%-58.3%$52.02M$145.24M-5.95380Upcoming EarningsShort Interest ↑News CoveragePMVPPMV Pharmaceuticals2.2607 of 5 stars$1.00-3.8%$5.67+466.7%-46.2%$51.93MN/A-1.0050Upcoming EarningsNews CoverageGap UpAVTXAvalo Therapeutics3.8827 of 5 stars$4.73-1.0%$33.00+597.7%-68.5%$50.48M$441,000.000.0040Gap UpCTORCitius OncologyN/A$0.70-4.0%$3.00+328.5%N/A$50.09MN/A0.00N/ANews CoveragePositive NewsGap DownPRLDPrelude Therapeutics2.9002 of 5 stars$0.89-1.6%$4.00+351.2%-75.4%$50.05M$7M-0.50120Upcoming EarningsAnalyst ForecastNews CoverageQNCXQuince Therapeutics2.8452 of 5 stars$1.13-7.9%$8.00+606.1%+8.7%$49.99MN/A-0.9160News CoverageHigh Trading VolumeICCCImmuCell0.9604 of 5 stars$5.50+0.0%N/A+7.5%$49.42M$26.49M-11.0070Positive News Related Companies and Tools Related Companies OKYO Pharma Alternatives PepGen Alternatives Immuneering Alternatives Karyopharm Therapeutics Alternatives PMV Pharmaceuticals Alternatives Avalo Therapeutics Alternatives Citius Oncology Alternatives Prelude Therapeutics Alternatives Quince Therapeutics Alternatives ImmuCell Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MEIP) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MEIP Stock Free MEIP Stock Alerts